Latest Articles

Publication Date
New therapy bests chemo to improve survival in endometrial cancer - Rare Cancer News

New therapy bests chemo to improve survival in endometrial cancer Rare Cancer News

Published: May 20, 2026, 1:14 p.m.
Endometriosis-related alterations in the endometrium revealed by integrated single-cell and AI-powered approaches.

Endometriosis, affecting 1 in 9 women, presents treatment and diagnostic challenges. To address these issues, we generated a comprehensive single-cell atlas of endometrial tissue, comprising 466,371 cells from 35 endometriosis …

Published: May 20, 2026, midnight
Merck’s billion-dollar Kelun bet pays off as TROP2 improves survival in endometrial cancer - BioSpace

Merck’s billion-dollar Kelun bet pays off as TROP2 improves survival in endometrial cancer BioSpace

Published: May 19, 2026, 11:19 a.m.
Merck-Kelun ADC boosts survival in phase 3 endometrial cancer, stokes TROP2 race - CHOSUNBIZ - Chosunbiz

Merck-Kelun ADC boosts survival in phase 3 endometrial cancer, stokes TROP2 race - CHOSUNBIZ Chosunbiz

Published: May 19, 2026, 6:54 a.m.
Sacituzumab Tirumotecan Improves Survival in Advanced Endometrial Cancer - Targeted Oncology

Sacituzumab Tirumotecan Improves Survival in Advanced Endometrial Cancer Targeted Oncology

Published: May 18, 2026, 1:33 p.m.
Merck endometrial cancer drug meets survival goals in phase 3 trial - StreetInsider

Merck endometrial cancer drug meets survival goals in phase 3 trial StreetInsider

Published: May 18, 2026, 10:47 a.m.
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Business Wire

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Business Wire

Published: May 18, 2026, 10:45 a.m.
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Yahoo! Finance Canada

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Yahoo! Finance …

Published: May 18, 2026, 10:45 a.m.
Endometriosis and ovarian cancer: epidemiological evidence, molecular insights, and clinical decision-making.

Endometriosis, particularly ovarian endometrioma, is associated with a 2-fold increased risk of ovarian cancer (OC), especially the clear cell and endometrioid subtypes. However, the absolute lifetime risk of OC in …

Published: May 17, 2026, midnight
Common Gynecologic Issues in Patients Post-Kidney Transplantation.

Advances in kidney transplantation have transformed survival and quality of life for women with end-stage renal disease, necessitating a focus on long-term health care for this population. Female kidney transplant …

Published: May 15, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!